Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc.(BIO)股票分析

$364.820

+2.408 (+0.66%)收盤時

Loading chart…
最高
368.540
開盤
364.900
成交量加權均價
364.41
成交量
247.83K
市值
7.76B
最低
359.880
成交金額
90.31M
企業價值/稅息折舊攤銷前利潤(TTM)
22.48

Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.

AI 分析 of Bio-Rad Laboratories, Inc. (BIO)

持有

Bio-Rad Laboratories Inc is currently a hold. The stock is trading at $366.16, which is close to the analyst price target of $390, indicating limited upside potential at this moment. The RSI is at 44.39, suggesting it is nearing oversold territory, but not yet in a strong buy zone. The forward P/E ratio is 41.32, which is high, indicating that the stock may be overvalued compared to its earnings potential. The main risk is the recent decline in the Life Science segment, which reported a 4.1% decrease in sales year-over-year, reflecting challenges in the academic research market. Overall, while there are some positive indicators, the current price and valuation metrics suggest that it may be prudent to hold rather than buy at this time.

分析師評級(4)

-6.80% 下跌空間
買進
4 買進
0 持有
0 賣出
目前: 364.82
最低
340.00
平均
340.00
最高
340.00

RBC Capital

2026-08-07

目標價

$390

優於大盤

Wells Fargo

2026-05-25

目標價

$310

Equal Weight

RBC Capital

2026-05-14

目標價

$320

優於大盤

Wells Fargo

2026-05-01

目標價

$290

Equal Weight

Citi

2026-04-07

目標價

$300

中性

估值指標

Bio-Rad Laboratories, Inc.(BIO)目前預期本益比為 41.32,5 年平均預期本益比為 33.15。

預期本益比

合理
5 年均值 P/E
33.15
目前P/E
41.32
高估
41.39
低估
24.91

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
20.62
目前EV/EBITDA
22.48
高估
26.72
低估
14.52

預期股價營收比

合理
5 年均值 P/S
4.01
目前P/S
3.70
高估
5.33
低估
2.69

Alphio AI 對 BIO 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%BIO

$211.45

情境價格

基

基準

基準 · 50%BIO

$204.69

情境價格

悲

悲觀

悲觀 · 25%BIO

$154.89

情境價格

持有 BIO 的大戶

F

First Pacific Advisors, LP

+ 持有BIO

+2.03%

3個月報酬率

H

Hosking Partners LLP

+ 持有BIO

+1.54%

3個月報酬率

A

Ariel Investments, LLC

+ 持有BIO

-3.36%

3個月報酬率

D

Deerfield Management Company, L.P.

+ 持有BIO

-6.90%

3個月報酬率

事件時間軸

2026-09-24 (ET)

06:30:00

Biodesix Advances Tumor-Informed and Tumor-Naive MRD Solutions

2026-08-04 (ET)

17:00:00

Bio-Rad Implements Restructuring Plan Estimated Costs Up to $90 Million

16:30:00

Company Expects 2026 Non-GAAP Revenue to Decline Approximately 3%

16:30:00

Bio-Rad Reports Q2 Revenue of $651M, Beating Expectations

2026-07-21 (ET)

10:30:00

Sartorius Shares Drop After Competitor Earnings Report

資訊

BIO 常見問題 —— 由 Alphio AI 解答

Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Bio-Rad Laboratories Inc is currently a hold. The stock is trading at $366.16, which is close to the analyst price target of $390, indicating limited upside potential at this moment. The RSI is at 44.39, suggesting it is nearing oversold territory, but not yet in a strong buy zone. The forward P/E ratio is 41.32, which is high, indicating that the stock may be overvalued compared to its earnings potential. The main risk is the recent decline in the Life Science segment, which reported a 4.1% decrease in sales year-over-year, reflecting challenges in the academic research market. Overall, while there are some positive indicators, the current price and valuation metrics suggest that it may be prudent to hold rather than buy at this time.

4 analysts cover BIO: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 340.00.

TrendCircuit2026/9/13

Didn't do anything, just went to the bathroom, and when I came back the chart had already done the work for me. When the market dumped early on, $BIO's bounce looked weak no matter how you read it. Every step down from the high came with volume, but the rebound kept getting lighter. Overhead trapped positions were pressing down clearly, funds just wanted to use the bounce to exit, nobody really wanted to buy. I was watching the short direction at 0.03161, with protection set at the upper edge of the bounce platform. At the time I only reminded one thing: don't try to catch a bounce in the early stage of a breakdown. If your hands are itching, go to the bathroom and wash your face. Came back and refreshed, price had already reached 0.02549, position return sitting at +1376.01%. Everyone on board should be feeling good. I took 80% off the table first, moved protection on the remaining 20% to breakeven. If it keeps dropping, let it drop, if it breaks the previous low there's another leg to capture; if it bounces back, this trade won't turn from profit into loss. Risk control done upfront is called being rational; cutting after losses is called cutting your losses. Don't chase shorts now, wait for a bounce to a structural level before acting. If the next shot doesn't come, wait patiently. The market won't only open its door once. $ADA $ETH

展開
TrendCircuit2026/9/11

I was about to go vent on the forum, then I checked my balance and decided to let it go. The market is always right 😮💨 When the morning session dumped, $BIO bounced and it actually looked decent for a moment. But the more I watched the order book, the more something felt off. Every push up came with no volume, a classic sign of weak follow-through. That kind of bounce looks lively, but nobody is actually stepping in to buy. The chart keeps teaching you lessons, most people just choose to sleep through class. I went ahead and opened a short at 0.03161. Someone said I was late to the trade. I didn't bother arguing, just waited for the result. Price just dropped to 0.02504, and my position PnL hit +1479.26%. It was slow at first, but once it moved, it really moved. Feels good. Nailing the rhythm matters more than anything 😎 I took 80% off the table and moved my stop on the remaining 20% back to breakeven. Whether it bounces from here or keeps grinding down, I won't be stressed either way. The prerequisite for compounding is staying alive. The shortcut to getting rich is usually going to zero. I'd rather miss a limit-up than try to catch a falling knife and end up with bloody hands. Don't chase here. Chasing at key levels is how you get hurt. I'll wait for the next signal. $XRP $LAB

展開
TrendCircuit2026/9/11

I opened the charts this morning, rubbed my eyes, and gave myself a little slap to make sure I wasn't seeing things. No trades, no analysis, just pure luck and stubbornness. Saying that record out loud feels embarrassing, but honestly, it feels great. Panic comes from having no plan, losses come from overthinking. I just sat there quietly watching it perform. When the screen was full of green, some people were panicking, but I found it interesting. Thinking back to a few days ago, the last look before bed, the trend clearly had no strength, the bounce was weak, and volume wasn't following at all. Funds wanted to push it up, but even they didn't dare enter. The fake breakout smell was right in your face. My only thought at the time was that this kind of bounce wouldn't last past the third watch. Short above 0.03161, now $BIO is at 0.02458, unrealized gain +1573.54%. This one was just the market in a good mood, handing money over. But even with the win, position management still matters. Everyone note the position moves: take profit on 80% first to lock in gains, move the stop on the remaining 20% to near cost, and let it run a bit. Risk control done upfront is called being rational; cutting after a loss is called a last resort. Don't get jealous of this level now, this isn't the time to chase. If you missed the rhythm, you missed it. Wait for a more comfortable spot next round. I'll keep watching the charts and call it as soon as there's a signal. The market never lacks opportunities, it lacks the patience to wait. Everyone keep your hands tied. $SNDK $SOL

展開
註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易